Director at West Pharmaceutical (WST) receives 791 restricted stock units

Rhea-AI Filing Summary

Pucci Paolo reported acquisition or exercise transactions in this Form 4 filing.

West Pharmaceutical Services director Paolo Pucci received an equity grant in the form of restricted stock units. He was awarded 791 units of common stock on the reported date, increasing his direct holdings to 11,854.297 shares.

The footnote explains that these restricted stock units will vest in full on the date of the next annual shareholder meeting and will then be distributed under the company’s Deferred Compensation Plan for Outside Directors. This is a compensation-related award rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pucci Paolo

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	791	$0.00	--

Holdings After Transaction: Common Stock — 11,854.297 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock units granted: 791 units Shares held after transaction: 11,854.297 shares

2 metrics

Restricted stock units granted 791 units Equity award to director on reported transaction date

Shares held after transaction 11,854.297 shares Total direct holdings following grant

Key Terms

restricted stock units, Deferred Compensation Plan for Outside Directors, Form 4

3 terms

restricted stock units financial

"These shares of restricted stock units will vest in full on the date"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Deferred Compensation Plan for Outside Directors financial

"will be distributable under the terms of the Deferred Compensation Plan for Outside Directors"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pucci Paolo

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		A		791(1)	A	$0	11,854.297	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

	/s/ Louis Lalli, as an agent for Paolo Pucci	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did West Pharmaceutical (WST) director Paolo Pucci report on this Form 4?

Paolo Pucci reported receiving 791 restricted stock units of West Pharmaceutical common stock as a compensation award. These units increase his direct equity exposure as a director and are structured to vest at the next annual shareholder meeting before being distributed.

How many West Pharmaceutical (WST) shares does Paolo Pucci hold after this grant?

After the grant, Paolo Pucci holds 11,854.297 shares of West Pharmaceutical common stock directly. This total includes the newly awarded 791 restricted stock units, which convert into common stock upon vesting and distribution under the company’s deferred compensation plan.

Was the West Pharmaceutical (WST) transaction a market purchase or a compensation award?

The transaction was a compensation-related award, not an open-market purchase. The filing uses code A for a grant or award, and the footnote clarifies these are restricted stock units that will vest and be distributed according to the Deferred Compensation Plan for Outside Directors.

When will Paolo Pucci’s West Pharmaceutical (WST) restricted stock units vest?

The restricted stock units will vest in full on the date of the next annual shareholder meeting. After vesting, they will be distributed under West Pharmaceutical’s Deferred Compensation Plan for Outside Directors, converting into common stock according to the plan’s terms.

What is the significance of the Deferred Compensation Plan for Outside Directors at West Pharmaceutical (WST)?

The Deferred Compensation Plan for Outside Directors governs how equity awards like restricted stock units are distributed. For this grant, it specifies that units vest at the next annual shareholder meeting and are then delivered as common stock, aligning director compensation with shareholder interests.